Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Top-Institutions - MDSpire

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • By

  • Keyuan Du

  • Chenglong Duan

  • Jiaqi Zhang

  • Jianing Zhang

  • Jinsui Du

  • Yi Pan

  • Zhihao Liu

  • Chenrong Zhang

  • Yuhan Zhang

  • Yibin Zhang

  • Xuan Zhang

  • Zhongxia Sheng

  • Bin Wang

  • Yu Ren

  • Lizhe Zhu

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    National Jewish Health
    National Jewish Health

    Denver, Colorado

    Key Differentiators

    • Pulmonology
    • Oncology

Original Source(s)

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • by Keyuan Du, Chenglong Duan, Jiaqi Zhang, Jianing Zhang, Jinsui Du, Yi Pan, Zhihao Liu, Chenrong Zhang, Yuhan Zhang, Yibin Zhang, Xuan Zhang, Zhongxia Sheng, Bin Wang, Yu Ren, Lizhe Zhu

  • June 10, 2026

Related Content

The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

Impact of body mass index on dietary habits and health behaviors in breast cancer patients

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report